INSMED INCORPORATED (NASDAQ:INSM) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
ITEM 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On January9, 2019, Dr.Paul D. Streck, the Chief Medical Officer of Insmed Incorporated (the “Company”), notified the Company of his resignation, effective January18, 2019, to pursue an employment opportunity on the West Coast. Dr.Streck has advised the Company that he intends to work with the Company in an advisory capacity subsequent to his departure to assist in the transition of his responsibilities. The Company has commenced a search for Dr.Streck’s successor. Dr.Streck’s resignation does not reflect any disagreement with the Company.
About INSMED INCORPORATED (NASDAQ:INSM)
Insmed Incorporated is a biopharmaceutical company. The Company operates in the segment of development and commercialization of inhaled therapies for patients with serious lung diseases. The Company’s lead product candidate, ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for patients with nontuberculous mycobacteria (NTM) lung disease, a rare and often chronic infection that is capable of causing irreversible lung damage and can be fatal. The Company’s earlier stage pipeline includes INS1009, a nebulized prodrug formulation of treprostinil, a vasodilator of pulmonary arterial vascular beds. The Company is conducting a global Phase III clinical study of ARIKAYCE (the 212 or CONVERT study) in adult patients with NTM lung disease caused by Mycobacterium avium complex (MAC), the infective species in NTM lung disease in the United States, Europe and Japan.